EPISODE · Mar 11, 2022 · 11 MIN
Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication
from MS News & Perspectives · host MS News Today
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, covers how MS patients on Mavenclad are less likely to experience a disease relapse than those on other oral DMTs like Gilenya, Tecfidera, or Aubagio.He also reads “The Double-Edged Sword of Fatigue Medications”, from Beth Ullah's column "Through the Looking Glass".=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/
Embed this episode
NOW PLAYING
Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.